rivastigmine has been researched along with tacrine in 119 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (10.08) | 18.2507 |
| 2000's | 58 (48.74) | 29.6817 |
| 2010's | 36 (30.25) | 24.3611 |
| 2020's | 13 (10.92) | 2.80 |
| Authors | Studies |
|---|---|
| Brossi, A; Greig, NH; Holloway, HW; Whittaker, NF; Yu, QS; Zhu, X | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Alley, GM; Brossi, A; Deschamps, JR; Greig, NH; Holloway, HW; Kulkarni, SS; Lahiri, DK; Luo, W; Parrish, D; Yu, QS; Zhan, M | 1 |
| Brossi, A; Greig, NH; Holloway, HW; Kulkarni, SS; Lahiri, DK; Luo, W; Parrish, DA; Shafferman, A; Tweedie, D; Yu, QS | 1 |
| Andrisano, V; Banzi, R; Bartolini, M; Bergamini, C; Bolognesi, ML; Cattaneo, A; Cavalli, A; Fato, R; Hrelia, P; Lenaz, G; Melchiorre, C; Minarini, A; Recanatini, M; Rosini, M; Tarozzi, A; Tumiatti, V | 1 |
| Bolognesi, ML; Cavalli, A; Melchiorre, C; Minarini, A; Recanatini, M; Rosini, M; Tumiatti, V | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Agnusdei, M; Belinskaya, T; Borriello, M; Brindisi, M; Butini, S; Campiani, G; Catalanotti, B; Fattorusso, C; Fiorini, I; Gemma, S; Nacci, V; Novellino, E; Panico, A; Persico, M; Ros, S; Saxena, A | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chaudhaery, SS; Nath, C; Nazir, A; Roy, KK; Sammi, SR; Saxena, AK; Saxena, G; Shakya, N | 1 |
| Bajda, M; Guzior, N; Malawska, B; Więckowska, A | 1 |
| Al-Rashid, ZF; Hsung, RP | 2 |
| Boido, V; Carotti, A; Catto, M; Giangreco, I; Nicolotti, O; Novelli, F; Pisani, L; Sparatore, A; Sparatore, F; Tasso, B; Tonelli, M | 1 |
| Bazureau, JP; Burgy, G; Carreaux, F; Cochet, C; Delhommel, F; Durieu, E; Elkins, JM; Filippakopoulos, P; Knapp, S; Lo, DC; Meijer, L; Oberholzer, AE; Pearl, LH; Schmid, RS; Soundararajan, M; Tahtouh, T | 1 |
| Chander, S; Nath, C; Roy, KK; Saxena, AK; Tota, S; Tripathi, T | 1 |
| Carotti, A; Catto, M; Cellamare, S; Leonetti, F; Nicolotti, O; Pesce, P; Pisani, L; Stefanachi, A | 1 |
| Hong, C; Li, Y; Luo, W; Su, LP; Su, YB; Tian, RG; Wang, CJ; Wang, YQ; Yue, JJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Brus, B; Colletier, JP; Coquelle, N; Gobec, S; Kos, J; Košak, U; Pišlar, A; Stojan, J; Turk, S | 1 |
| Bajda, M; Czarnecka, K; Girek, M; Gumieniczek, A; Jończyk, J; Malawska, B; Mikiciuk-Olasik, E; Olszewska, P; Sikora, J; Skibiński, R; Szymański, P | 1 |
| Amooru, GD; Ampasala, DR; Darla, MM; Devineni, SR; Eadlapalli, S; Kotapati, KV; Palaka, BK; Penumala, M; Shaik, JB; Vadde, R | 1 |
| Chang, CC; Chang, LP; Chen, Y; Hong, C; Luo, W; Wang, CJ; Wang, T; Xie, SQ; Yang, YC | 1 |
| Orvig, C; Patrick, BO; Rodríguez-Rodríguez, C; Telpoukhovskaia, MA | 1 |
| Hoda, N; Jameel, E; Jayaram, B; Kumar, J; Maqbool, M; Meena, P; Mobashir, M; Shandilya, A; Singh, A; Tiwari, M | 1 |
| Aitken, L; Benek, O; Dohnal, V; Dolezal, R; Guest, P; Gunn-Moore, F; Hroch, L; Janockova, J; Kuca, K; Musil, K; Musilek, K; Smith, TK; Soukup, O | 1 |
| Brazzolotto, X; Chan, S; De la Mora, E; Deora, GS; Dighe, SN; Nachon, F; Parat, MO; Ross, BP | 1 |
| Bajda, M; Gobec, S; Godyń, J; Janockova, J; Jończyk, J; Knez, D; Korabecny, J; Malawska, B; Mika, K; Panek, D; Soukup, O; Wichur, T; Więckowska, A | 1 |
| Akbarzadeh, T; Asatouri, R; Karimpour-Razkenari, E; Khanavi, M; Mahdavi, M; Moghadam, FH; Najafi, Z; Saeedi, M; Sharifzadeh, M; Vafadarnejad, F | 1 |
| Azzouz, R; Bohn, P; Gembus, V; Levacher, V; Papamicaël, C; Peauger, L; Sopková-de Oliveira Santos, J; Ţînţaş, ML | 1 |
| Andrisano, V; Apperley, KYP; Bartolini, M; Baschieri, A; Basso, M; Chen, HH; De Simone, A; Guardigni, M; Keillor, JW; Kobrlova, T; Milelli, A; Montanari, S; Soukup, O; Valgimigli, L | 1 |
| Ibrar, A; Khan, I; Saeed, F; Shehzadi, SA | 1 |
| Brazzolotto, X; Colletier, JP; Coquelle, N; Gobec, S; Jukič, M; Knez, D; Kos, J; Mravljak, J; Nachon, F; Pišlar, A; Sova, M; Žakelj, S | 1 |
| Kumar, A; Mishra, P; Panda, G | 1 |
| Abu-Serie, MM; AlFadly, ED; Bakkar, NZ; Bartolini, M; Belal, ASF; El-Yazbi, AF; Elkazaz, S; Elzahhar, PA; Ghareeb, DA; Iriepa, I; Janockova, J; Kobeissy, F; Moraleda, I; Rafeh, RW; Saudi, MNS; Shaltout, H; Soukup, O; Tramarin, A | 1 |
| Bolognesi, ML; da Costa Nunes, JL; de Oliveira Miranda, C; de Oliveira, AS; Gandini, A; Gervasoni, S; Jung, M; Kobrlova, T; Massenzio, F; Monti, B; Petralla, S; Rossi, M; Senger, J; Simões Heyn Roth Cardoso, G; Soares Romeiro, LA; Soukup, O; Vistoli, G | 1 |
| Chen, YP; Guo, HY; Luo, W; Lv, JW; Ma, J; Song, ZY; Wang, CJ; Wang, T; Zhang, ZY | 1 |
| do Carmo Carreiras, M; Ismaili, L; Marco-Contelles, J | 1 |
| Cui, Z; Gao, J; Geng, H; Li, D; Li, H; Zhou, B; Zhou, L | 1 |
| Benek, O; Benkova, M; Dolezal, R; Hepnarova, V; Hrabinova, M; Janockova, J; Jun, D; Kobrlova, T; Korabecny, J; Kucera, T; Mezeiova, E; Prchal, L; Sobolova, K; Soukup, O | 1 |
| Boulouard, M; Claeysen, S; Corvaisier, S; Dallemagne, P; Davis, A; Freret, T; Hatat, B; Lalut, J; Lecoutey, C; Rochais, C; Since, M; Sopková-de Oliveira Santos, J; Toublet, FX | 1 |
| Andrys, R; Capek, J; Handl, J; Hrabinova, M; Janockova, J; Kobrlova, T; Korabecny, J; Marco-Contelles, JL; Mezeiova, E; Micankova, P; Muckova, L; Nepovimova, E; Pejchal, J; Rousar, T; Simunkova, M; Soukup, O; Valko, M | 1 |
| Brazzolotto, X; Bucki, A; Gobec, S; Godyń, J; Góral, I; Głuch-Lutwin, M; Honkisz-Orzechowska, E; Knez, D; Kołaczkowski, M; Latacz, G; Malawska, B; Panek, D; Pasieka, A; Sabate, R; Siwek, A; Wichur, T; Więckowska, A | 1 |
| Bayomi, SM; El-Subbagh, HI; Ghaly, MA; Saad, KM; Waly, OM | 1 |
| Decker, M; Hofmann, J; Maurice, T; Spatz, P; Steinmüller, S; Zimmermann, T | 1 |
| Eckroat, TJ; Reiland, KM | 1 |
| Palacios, JM | 1 |
| Schneider, LS | 2 |
| Honma, A | 1 |
| Brefel-Courbon, C; Freslon, JL; Lazartigues, E; Montastruc, JL; Pelat, M; Rascol, O; Tellioglu, T; Tran, MA | 1 |
| Lacomblez, L | 1 |
| Derquesné, C | 1 |
| Dom, R; Lemière, J; Van Gool, D | 1 |
| Kosasa, T; Kuriya, Y; Matsui, K; Yamanishi, Y | 2 |
| Kosasa, T; Kuriya, Y; Yamanishi, Y | 1 |
| Bejar, C; Wang, RH; Weinstock, M | 1 |
| Burns, A; Page, S; Russell, E | 1 |
| Stahl, SM | 1 |
| Dronfield, S; Egan, K; Green, AR; Marsden, CA | 1 |
| Giacobini, E | 1 |
| Grutzendler, J; Morris, JC | 1 |
| Kosasa, T; Kuriya, Y; Ogura, H; Yamanishi, Y | 1 |
| Hake, AM | 1 |
| Lampley-Dallas, VT | 1 |
| Gavrilova, SI; Zharikov, GA | 1 |
| Winblad, B | 1 |
| Allain, H; Bentue-Ferrer, D; Lecavorzin, P; Polard, E; Reymann, JM; Tribut, O | 1 |
| Klein, C; Rabey, JM; Werber, AE | 1 |
| Robert, P | 1 |
| Blount, PJ; McDeavitt, JT; Nguyen, CD | 1 |
| Jann, MW; Shirley, KL; Small, GW | 1 |
| Ott, BR | 1 |
| Castro, A; Martinez, A | 1 |
| Tang, XC; Zhao, Q | 1 |
| Kamei, H; Nabeshima, T; Noda, Y | 1 |
| Almkvist, O; Blennow, K; Hellström-Lindahl, E; Nordberg, A; Stefanova, E | 1 |
| Hartmann, S; Möbius, HJ | 1 |
| Albuquerque, EX; Christner, C; Fehrenbacher, A; Höffle, A; Jostock, R; Lübbert, H; Ludwig, J; Maelicke, A; Pereira, EF; Radina, M; Samochocki, M; Ullmer, C; Zerlin, M | 1 |
| Gandelman-Marton, R; Klein, C; Rabey, JM; Werber, EA | 1 |
| Butler, R; Prabhakaran, P; Warner, J | 1 |
| Rakonczay, Z | 1 |
| Fuchsberger, T; Hampel, H; Möller, HJ | 1 |
| Haen, E; Ibach, B | 1 |
| Darreh-Shori, T; Flores-Flores, C; Guan, ZZ; Hellström-Lindahl, E; Nordberg, A; Soreq, H | 1 |
| Caricati-Neto, A; D'angelo, LC; Garcia, AG; Hyppolito Jurkiewicz, N; Jurkiewicz, A; Reuter, H | 1 |
| Simard, M; van Reekum, R | 1 |
| Arya, P; Butler, R; Warner, J | 2 |
| Bermudez, I; Groot-Kormelink, PJ; Smulders, CJ; van Kleef, RG; Vijverberg, HP; Zwart, R | 1 |
| Ben-Hur, T; Ben-Menachem, O; Gilboa, A; Pollak, Y; Soreq, H; Yirmiya, R | 1 |
| Aisen, PS | 1 |
| Butler, R; Warner, J; Wuntakal, B | 1 |
| Cummings, JL; Ringman, JM | 1 |
| Beck, C; Blank, K; Colenda, CC; Doraiswamy, MP; Kalunian, DA; Lyketsos, CG; Yaffe, K | 1 |
| Gruber, J; Hollenack, K; O'Shea, T; Stefanacci, R; Tangalos, EG; Zarowitz, BJ | 1 |
| Agrawal, R; Nath, C; Shukla, R; Tyagi, E | 1 |
| Ballard, CG; Chalmers, KA; Love, S; McKeith, IG; O'Brien, JT; Perry, EK; Todd, C; Wilcock, G | 1 |
| McCain, KR; Sawyer, TS; Spiller, HA | 1 |
| Bajda, M; Malawska, B; Musiał, A | 1 |
| Adelman, A; Campos-Outcalt, D; Cross, JT; Forciea, MA; Hopkins, R; Mehr, D; Owens, DK; Qaseem, A; Santaguida, P; Schellhase, K; Shekelle, P; Snow, V | 1 |
| Booker, L; Cowan, D; Ismaila, A; Levine, M; Oremus, M; Patterson, C; Raina, P; Santaguida, P | 1 |
| Graham, L | 1 |
| Graham, K; Josif, S | 1 |
| Ehret, A; Feuerstein, TJ; Förster, S; Jackisch, R; Kammerer, M; Rothmaier, AK; Zentner, J | 1 |
| Okochi, M; Takeda, M; Tanaka, T | 1 |
| Atri, A | 1 |
| Ahnaou, A; Drinkenburg, WH; Huysmans, H; Jacobs, T | 1 |
| Bezerra da Silva, C; Dalarmi, L; Dallarmi Miguel, M; de Fátima Gaspari Dias, J; de Oliveira, M; Elifio-Esposito, S; Fialho do Nascimento, K; Gomes Miguel, O; Moura Burci, L; Pott, A; Warumby Zanin, SM | 1 |
| Afshar, Z; Akbarzadeh, T; Edraki, N; Hariri, R; Karimpour-Razkenari, E; Khanavi, M; Mahdavi, M; Moghadam, FH; Najafi, Z; Sabourian, R; Saeedi, M; Safavi, M; Shafiee, A | 1 |
| Godyń, J; Malawska, B; Panek, D; Pasieka, A; Wichur, T | 1 |
| Alcaro, S; Borges, F; Chavarria, D; Gaspar, A; Mesiti, F | 1 |
| Asadipour, A; Eskandari, K; Pourshojaei, Y | 1 |
| Ahmed, M; Aleya, L; Ashraf, GM; Barreto, GE; Begum, MM; Kabir, MT; Mathew, B; Rahman, MS; Thangapandiyan, S; Uddin, MS | 1 |
| Aksoz, BE; Aksoz, E | 1 |
| Chmielewska, K; Dzierzbicka, K; Inkielewicz-Stepniak, I; Kowalski, S; Przybyłowska, M | 1 |
| Eriksson, LA; Gholami, A; Minai-Tehrani, D | 1 |
39 review(s) available for rivastigmine and tacrine
| Article | Year |
|---|---|
Multi-target-directed ligands to combat neurodegenerative diseases.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Binding Sites; Calcium Channel Blockers; Chelating Agents; Cholinesterase Inhibitors; Humans; Huntington Disease; Ligands; Multiple Sclerosis; Neurodegenerative Diseases; Neurofibrillary Tangles; Neurotransmitter Agents; Parkinson Disease; Plaque, Amyloid | 2008 |
Developing hybrid molecule therapeutics for diverse enzyme inhibitory action: Active role of coumarin-based structural leads in drug discovery.
Topics: Aldehyde Reductase; Alkaline Phosphatase; Cholinesterases; Coumarins; Drug Design; Enzymes; Glucosidases; Humans; Molecular Docking Simulation; Monoamine Oxidase | 2018 |
Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer's disease (1998-2018).
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Cholinesterases; Drug Design; Humans; Ligands; Neuroprotective Agents | 2019 |
Propargylamine-derived multi-target directed ligands for Alzheimer's disease therapy.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Cholinesterases; Humans; Ligands; Monoamine Oxidase; Neuroprotective Agents; Oxidative Stress; Pargyline; Propylamines | 2020 |
New therapeutic approaches to Alzheimer's disease.
Topics: Alzheimer Disease; Antioxidants; Carbamates; Cholinergic Agents; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine; Trichlorfon | 1996 |
[Therapeutic agents for Alzheimer's disease].
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Humans; Indans; Monoamine Oxidase Inhibitors; Neuropeptides; Phenylcarbamates; Piperidines; Receptor, Muscarinic M1; Receptors, Muscarinic; Rivastigmine; Spiro Compounds; Tacrine | 1998 |
New therapeutic approaches to cognitive impairment.
Topics: Aged; Alzheimer Disease; Antioxidants; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Humans; Indans; Monoamine Oxidase Inhibitors; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine; Trichlorfon | 1998 |
Treatment of Alzheimer's disease: an evaluation of the cholinergic approach.
Topics: Acetylcholine; Alzheimer Disease; Animals; Carbamates; Chemical and Drug Induced Liver Injury; Cholinergic Agents; Cholinergic Fibers; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Double-Blind Method; Drug Evaluation, Preclinical; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Receptors, Cholinergic; Receptors, Muscarinic; Receptors, Nicotinic; Rivastigmine; Tacrine | 1999 |
Cholinesterase inhibitors stabilize Alzheimer's disease.
Topics: Alzheimer Disease; Brain; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine; Trichlorfon | 2000 |
Cholinesterase inhibitors for Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Cost-Benefit Analysis; Donepezil; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 2001 |
Use of cholinesterase inhibitors for treatment of Alzheimer disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 2001 |
[Current strategies of pathogenetic therapy of Alzheimer's disease].
Topics: Aged; Alzheimer Disease; Amino Acids; Aminoquinolines; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Dopamine Agents; Estrogens; Ginkgo biloba; Humans; Indans; Memantine; Monoamine Oxidase Inhibitors; Multicenter Studies as Topic; Neuronal Plasticity; Neuroprotective Agents; Neurotransmitter Agents; Nicergoline; Nootropic Agents; Phenylcarbamates; Phytotherapy; Piperidines; Piracetam; Pyrithioxin; Rivastigmine; Selegiline; Tacrine; Time Factors | 2001 |
[Perspectives for drug treatment in Alzheimer's disease].
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Galantamine; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 2001 |
Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
Topics: Acetylcholine; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognitive Behavioral Therapy; Disease Progression; Donepezil; Galantamine; Humans; Indans; Neuroprotective Agents; Phenylcarbamates; Physostigmine; Piperidines; Rivastigmine; Tacrine; Time Factors; Treatment Outcome | 2002 |
Clinical use of cholinomimetic agents: a review.
Topics: Administration, Oral; Adult; Aged; Alzheimer Disease; Brain Injuries; Carbamates; Clinical Trials as Topic; Cytidine Diphosphate Choline; Donepezil; Female; Follow-Up Studies; Humans; Indans; Injections, Intravenous; Injury Severity Score; Male; Middle Aged; Parasympathomimetics; Phenylcarbamates; Physostigmine; Piperidines; Rivastigmine; Severity of Illness Index; Tacrine; Treatment Outcome | 2002 |
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
Topics: Aging; Alzheimer Disease; Biological Availability; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Interactions; Half-Life; Humans; Indans; Intestinal Absorption; Liver; Phenylcarbamates; Piperidines; Protein Binding; Rivastigmine; Tacrine; Tissue Distribution | 2002 |
Medical treatment of Alzheimer's disease: past, present, and future.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Forecasting; Galantamine; Humans; Indans; Male; Phenylcarbamates; Piperidines; Prognosis; Rivastigmine; Severity of Illness Index; Tacrine; Treatment Outcome | 2002 |
Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Binding Sites; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Design; Humans; Indans; Molecular Conformation; Molecular Structure; Phenylcarbamates; Piperidines; Rivastigmine; Structure-Activity Relationship; Tacrine | 2001 |
[Anti-dementia drugs for Alzheimer disease in present and future].
Topics: Acetylcholine; Alzheimer Disease; Amyloid beta-Peptides; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Design; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine; tau Proteins | 2002 |
Dementia.
Topics: Alzheimer Disease; Anticonvulsants; Antipsychotic Agents; Carbamates; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; Nootropic Agents; Phenylcarbamates; Phosphatidylcholines; Physostigmine; Phytotherapy; Piperidines; Rivastigmine; Tacrine; Vitamin E | 2003 |
[Current therapy of patients with dementia].
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Controlled Clinical Trials as Topic; Dementia; Dementia, Vascular; Donepezil; Dopamine Agents; Female; Galantamine; Ginkgo biloba; Humans; Indans; Male; Memantine; Meta-Analysis as Topic; Multicenter Studies as Topic; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Phytotherapy; Piperidines; Placebos; Plant Preparations; Prospective Studies; Rivastigmine; Tacrine; Time Factors | 2003 |
Acetylcholinesterase inhibition in Alzheimer's Disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 2004 |
The acetylcholinesterase inhibitors for treatment of cognitive and behavioral symptoms in dementia with Lewy bodies.
Topics: Aged; Basal Ganglia Diseases; Behavior; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition; Cognition Disorders; Donepezil; Humans; Indans; Lewy Body Disease; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Tacrine | 2004 |
Dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Cognition; Dementia; Donepezil; Galantamine; Ginkgo biloba; Haloperidol; Humans; Indans; Memantine; Olanzapine; Phenylcarbamates; Physostigmine; Phytotherapy; Piperidines; Risperidone; Rivastigmine; Selegiline; Tacrine; Vitamin E | 2004 |
Dementia.
Topics: Alzheimer Disease; Dementia; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Physostigmine; Phytotherapy; Piperidines; Rivastigmine; Tacrine | 2004 |
Pharmacologic treatment options in Alzheimer's disease: optimizing disease management.
Topics: Acetylcholine; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Disease Management; Donepezil; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Galantamine; Glutamic Acid; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Severity of Illness Index; Tacrine; Treatment Outcome | 2005 |
Dementia.
Topics: Alzheimer Disease; Benzodiazepines; Dementia; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; Memantine; Nootropic Agents; Olanzapine; Phenylcarbamates; Physostigmine; Phytotherapy; Piperidines; Rivastigmine; Selegiline; Tacrine | 2005 |
Current and emerging pharmacological treatment options for dementia.
Topics: Acetylcholine; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Humans; Indans; Lewy Body Disease; Neurodegenerative Diseases; Neuroprotective Agents; Parkinson Disease; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 2006 |
The application of evidence-based principles of care in older persons (issue 5): Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Evidence-Based Medicine; Geriatric Assessment; Humans; Indans; Mental Disorders; Nootropic Agents; Phenylcarbamates; Piperidines; Positron-Emission Tomography; Rivastigmine; Tacrine | 2007 |
Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment.
Topics: Alkaloids; Alzheimer Disease; Binding Sites; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Indole Alkaloids; Isoquinolines; Phenylcarbamates; Physostigmine; Piperidines; Propidium; Rivastigmine; Steroids; Tacrine | 2007 |
Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline.
Topics: Activities of Daily Living; Affect; Cholinesterase Inhibitors; Cognition; Dementia; Donepezil; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Quality of Life; Rivastigmine; Tacrine | 2008 |
Diagnosis and treatment of dementia with Lewy bodies.
Topics: Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Lewy Body Disease; Nootropic Agents; Phenylcarbamates; Piperidines; Prognosis; Rivastigmine; Tacrine | 2008 |
New drugs for Alzheimer's disease in Japan.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Discovery; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Japan; Memantine; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 2011 |
Effective pharmacological management of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Dementia; Disease Progression; Donepezil; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine; Time Factors; Treatment Outcome | 2011 |
Advances toward multifunctional cholinesterase and β-amyloid aggregation inhibitors.
Topics: Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Humans; Indans; Inhibitory Concentration 50; Piperidines; Rivastigmine; Tacrine | 2017 |
The chemistry toolbox of multitarget-directed ligands for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Chemistry Techniques, Synthetic; Donepezil; Dopamine Agents; Drug Design; Drug Discovery; Humans; Indans; Memantine; Molecular Targeted Therapy; Neuroprotective Agents; Nootropic Agents; Rivastigmine; Tacrine | 2019 |
Highly Significant Scaffolds to Design and Synthesis Cholinesterase Inhibitors as Anti-Alzheimer Agents.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Donepezil; Drug Design; Humans; Rivastigmine; Tacrine | 2019 |
Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Repositioning; Galantamine; Humans; Rivastigmine; Tacrine | 2019 |
Vital Role of Monoamine Oxidases and Cholinesterases in Central Nervous System Drug Research: A Sharp Dissection of the Pathophysiology.
Topics: Central Nervous System Agents; Central Nervous System Diseases; Cholinesterases; Combined Modality Therapy; Donepezil; Drug Design; Enzyme Inhibitors; Galantamine; Humans; Monoamine Oxidase; Rivastigmine; Structure-Activity Relationship; Tacrine | 2020 |
2 trial(s) available for rivastigmine and tacrine
| Article | Year |
|---|---|
Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Apolipoprotein E2; Apolipoprotein E4; Apolipoproteins E; Biomarkers; Brain; Carbamates; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Female; Genotype; Glucose; Humans; Male; Middle Aged; Peptide Fragments; Phenylcarbamates; Rivastigmine; Tacrine; tau Proteins | 2003 |
The clinical use of P300 event related potentials for the evaluation of cholinesterase inhibitors treatment in demented patients.
Topics: Acetylcholine; Aged; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Electroencephalography; Event-Related Potentials, P300; Female; Humans; Indans; Male; Middle Aged; Phenylcarbamates; Piperidines; Prospective Studies; Reaction Time; Rivastigmine; Tacrine; Treatment Outcome | 2003 |
78 other study(ies) available for rivastigmine and tacrine
| Article | Year |
|---|---|
Anticholinesterase activity of compounds related to geneserine tautomers. N-Oxides and 1,2-oxazines.
Topics: Acetylcholinesterase; Alkaloids; Butyrylcholinesterase; Cholinesterase Inhibitors; Cyclic N-Oxides; Humans; Isomerism; Oxazines; Structure-Activity Relationship | 2002 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Novel anticholinesterases based on the molecular skeletons of furobenzofuran and methanobenzodioxepine.
Topics: Acetylcholinesterase; Amyloid beta-Protein Precursor; Benzofurans; Butyrylcholinesterase; Carbamates; Cell Line; Cell Survival; Cholinesterase Inhibitors; Crystallography, X-Ray; Humans; Models, Molecular; Molecular Structure; Neurons; Oxepins; Structure-Activity Relationship | 2005 |
Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine.
Topics: Acetophenones; Acetylcholinesterase; Animals; Benzofurans; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Crystallography, X-Ray; Furans; Heterocyclic Compounds, 3-Ring; Humans; Models, Molecular; Oxepins; Stereoisomerism; Structure-Activity Relationship; Torpedo | 2006 |
Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Binding Sites; Butyrylcholinesterase; Cell Line; Cholinesterase Inhibitors; Humans; Ligands; Models, Molecular; NAD(P)H Dehydrogenase (Quinone); Oxidative Stress; Polyamines; Protein Binding; Quinones; Reactive Oxygen Species; Structure-Activity Relationship; Substrate Specificity | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors.
Topics: Acetylcholinesterase; Binding Sites; Butyrylcholinesterase; Cholinesterase Inhibitors; Computational Biology; Crystallography, X-Ray; Drug Design; Humans; Models, Molecular; Protein Conformation; Structure-Activity Relationship; Tacrine | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based virtual screening, synthesis, and pharmacology.
Topics: Acetylcholinesterase; Administration, Oral; Animals; Avoidance Learning; Caenorhabditis elegans; Carbamates; Catalytic Domain; Cholinesterase Inhibitors; Databases, Factual; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Male; Mice; Models, Molecular; Nootropic Agents; Quantitative Structure-Activity Relationship; Scopolamine | 2010 |
Novel alkyl- and arylcarbamate derivatives with N-benzylpiperidine and N-benzylpiperazine moieties as cholinesterases inhibitors.
Topics: Acetylcholinesterase; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Enzyme Activation; Kinetics; Models, Molecular; Molecular Structure; Piperazines; Piperidines; Stereoisomerism; Structure-Activity Relationship | 2010 |
(+)-Arisugacin A--computational evidence of a dual binding site covalent inhibitor of acetylcholinesterase.
Topics: Alzheimer Disease; Binding Sites; Cholinesterase Inhibitors; Computer Simulation; Inhibitory Concentration 50; Models, Biological; Models, Molecular; Molecular Structure; Pyrans | 2011 |
Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cattle; Cholinesterase Inhibitors; Crystallography, X-Ray; Dose-Response Relationship, Drug; Erythrocytes; Models, Molecular; Molecular Structure; Quinolizidines; Stereoisomerism; Structure-Activity Relationship | 2011 |
Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.
Topics: Alkaloids; Amyloid beta-Protein Precursor; Animals; Brain; Cell Death; Cell Line; Chromatography, Affinity; Crystallography, X-Ray; Cyclin-Dependent Kinase 2; Dioxoles; Dyrk Kinases; Glutamic Acid; Humans; Imidazoles; In Vitro Techniques; Mice; Models, Molecular; Molecular Structure; Neuroprotective Agents; Porifera; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyramidal Cells; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Stereoisomerism; Structure-Activity Relationship | 2012 |
Lead optimization studies towards the discovery of novel carbamates as potent AChE inhibitors for the potential treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Discovery; Mice; Models, Molecular; Molecular Dynamics Simulation; Molecular Structure; Structure-Activity Relationship | 2012 |
Design, synthesis and biological evaluation of coumarin alkylamines as potent and selective dual binding site inhibitors of acetylcholinesterase.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Binding Sites; Butyrylcholinesterase; Cattle; Cholinesterase Inhibitors; Coumarins; Horses; Humans | 2013 |
Design, synthesis and evaluation of novel 4-dimethylamine flavonoid derivatives as potential multi-functional anti-Alzheimer agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Butyrylcholinesterase; Cholinesterase Inhibitors; Dimethylamines; Drug Design; Flavonoids; Humans; Molecular Docking Simulation; Structure-Activity Relationship | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Discovery, biological evaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor.
Topics: Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Cell Line, Tumor; Cholinesterase Inhibitors; Chromatography, High Pressure Liquid; Crystallization; Drug Discovery; Humans; Mice; Molecular Docking Simulation; Peptide Fragments; Protein Aggregates; Stereoisomerism | 2014 |
A computational view on the significance of E-ring in binding of (+)-arisugacin A to acetylcholinesterase.
Topics: Acetylcholinesterase; Animals; Binding Sites; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Molecular Docking Simulation; Molecular Structure; Pyrans; Stereoisomerism; Structure-Activity Relationship | 2015 |
Synthesis, biological evaluation and molecular modeling of new tetrahydroacridine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acridines; Alzheimer Disease; Cholinesterase Inhibitors; Drug Design; Humans; Models, Molecular; Structure-Activity Relationship | 2015 |
Synthesis, pharmacological assessment, molecular modeling and in silico studies of fused tricyclic coumarin derivatives as a new family of multifunctional anti-Alzheimer agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Binding Sites; Butyrylcholinesterase; Chemistry Techniques, Synthetic; Cholinesterase Inhibitors; Computer Simulation; Coumarins; Drug Evaluation, Preclinical; Galantamine; Humans; Hydrogen Peroxide; Male; Mice, Inbred BALB C; Models, Molecular; Neuroprotective Agents; Neurotoxicity Syndromes | 2016 |
Design, synthesis and evaluation of novel 7-aminoalkyl-substituted flavonoid derivatives with improved cholinesterase inhibitory activities.
Topics: Animals; Butyrylcholinesterase; Catalytic Domain; Cell Survival; Cholinesterase Inhibitors; Cholinesterases; Dose-Response Relationship, Drug; Drug Design; Enzyme Activation; Flavonoids; Hep G2 Cells; Humans; Models, Molecular; Molecular Structure; PC12 Cells; Rats; Structure-Activity Relationship | 2016 |
In silico to in vitro screening of hydroxypyridinones as acetylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Molecular Docking Simulation; Molecular Structure; Pyridones; Structure-Activity Relationship | 2016 |
Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Butyrylcholinesterase; Cell Line, Tumor; Cell Survival; Chemistry Techniques, Synthetic; Cholinesterase Inhibitors; Drug Evaluation, Preclinical; Humans; Kinetics; Molecular Docking Simulation; Peptide Fragments; Protein Aggregates; Protein Conformation; Pyrimidines | 2016 |
Design, synthesis and in vitro evaluation of benzothiazole-based ureas as potential ABAD/17β-HSD10 modulators for Alzheimer's disease treatment.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; Alzheimer Disease; Animals; Benzothiazoles; Cell Survival; CHO Cells; Cricetulus; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Humans; Molecular Structure; Structure-Activity Relationship; Urea | 2016 |
Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.
Topics: Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Discovery; Drug Evaluation, Preclinical; Humans; Models, Molecular; Molecular Structure; Structure-Activity Relationship | 2016 |
Design, synthesis and biological evaluation of new phthalimide and saccharin derivatives with alicyclic amines targeting cholinesterases, beta-secretase and amyloid beta aggregation.
Topics: Amines; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Binding Sites; Blood-Brain Barrier; Cholinesterases; Drug Delivery Systems; Drug Design; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Molecular Structure; Peptide Fragments; Phthalimides; Protein Aggregation, Pathological; Protein Binding; Saccharin | 2017 |
Novel tacrine-1,2,3-triazole hybrids: In vitro, in vivo biological evaluation and docking study of cholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cell Death; Cell Line; Cell Line, Tumor; Cholinesterase Inhibitors; Humans; Kinetics; Male; Memory Disorders; Molecular Docking Simulation; Neurons; Neuroprotective Agents; Rats; Rats, Wistar; Structure-Activity Relationship; Tacrine; Triazoles | 2017 |
Donepezil-Based Central Acetylcholinesterase Inhibitors by Means of a "Bio-Oxidizable" Prodrug Strategy: Design, Synthesis, and in Vitro Biological Evaluation.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid; Animals; Cholinesterase Inhibitors; Donepezil; Drug Design; Female; Humans; Indans; Mice; Molecular Docking Simulation; Piperidines; Prodrugs | 2017 |
Hydroxy-substituted trans-cinnamoyl derivatives as multifunctional tools in the context of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cinnamates; Dose-Response Relationship, Drug; Free Radical Scavengers; Glycogen Synthase Kinase 3 beta; Molecular Structure; Stereoisomerism; Structure-Activity Relationship | 2017 |
Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Butyrylcholinesterase; Caco-2 Cells; Cell Line, Tumor; Cholinesterase Inhibitors; Drug Design; Humans; Ligands; Models, Molecular; Neuroprotective Agents; Piperidines | 2018 |
Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase.
Topics: Acetylcholine; Alzheimer Disease; Animals; Cell Line; Cholinesterase Inhibitors; Cyclooxygenase 2 Inhibitors; Drug Design; Humans; Inflammation; Lipoxygenase Inhibitors; Mice; Molecular Docking Simulation; Neurons; PC12 Cells; Rats; Semicarbazides; Triazoles | 2019 |
Novel Sustainable-by-Design HDAC Inhibitors for the Treatment of Alzheimer's Disease.
Topics: | 2019 |
Synthesis, in vitro and in vivo biological evaluation of novel graveolinine derivatives as potential anti-Alzheimer agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Behavior, Animal; Butyrylcholinesterase; Cell Survival; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Electrophorus; Hep G2 Cells; Horses; Humans; Male; Methoxsalen; Mice; Molecular Structure; PC12 Cells; Peptide Fragments; Rats; Structure-Activity Relationship | 2020 |
Simple analogues of natural product chelerythrine: Discovery of a novel anticholinesterase 2-phenylisoquinolin-2-ium scaffold with excellent potency against acetylcholinesterase.
Topics: Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Discovery; Humans; Inhibitory Concentration 50; Isoquinolines; Molecular Docking Simulation; Structure-Activity Relationship | 2020 |
Discovery of novel berberine derivatives with balanced cholinesterase and prolyl oligopeptidase inhibition profile.
Topics: Berberine; Blood-Brain Barrier; Cell Line, Tumor; Cholinesterase Inhibitors; Cholinesterases; Drug Design; Humans; Prolyl Oligopeptidases | 2020 |
Pleiotropic prodrugs: Design of a dual butyrylcholinesterase inhibitor and 5-HT
Topics: Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Electrophorus; Humans; Locomotion; Male; Mice; Models, Molecular; Molecular Structure; Prodrugs; Receptors, Serotonin; Structure-Activity Relationship | 2021 |
2-Propargylamino-naphthoquinone derivatives as multipotent agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Drug Design; Humans; Naphthoquinones; Structure-Activity Relationship | 2021 |
Discovery of 1-(phenylsulfonyl)-1H-indole-based multifunctional ligands targeting cholinesterases and 5-HT
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Cell Proliferation; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Discovery; Electrophorus; Hep G2 Cells; Horses; Humans; Indoles; Ligands; Mice; Microsomes, Liver; Molecular Docking Simulation; Molecular Structure; Protein Aggregates; Receptors, Serotonin; Structure-Activity Relationship; tau Proteins | 2021 |
Synthesis, biological evaluation, and molecular modeling simulations of new heterocyclic hybrids as multi-targeted anti-Alzheimer's agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Donepezil; Drug Design; Humans; Models, Molecular; Neuroprotective Agents; Tacrine | 2022 |
Novel benzimidazole-based pseudo-irreversible butyrylcholinesterase inhibitors with neuroprotective activity in an Alzheimer's disease mouse model.
Topics: | 2022 |
Selective butyrylcholinesterase inhibition by isatin dimers and 3-indolyl-3-hydroxy-2-oxindole dimers.
Topics: Acetylcholinesterase; Butyrylcholinesterase; Cholinesterase Inhibitors; Isatin; Molecular Docking Simulation; Structure-Activity Relationship | 2022 |
Alzheimer's disease: new pharmacological perspectives.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Dihydropyridines; Donepezil; Humans; Indans; Muscarinic Agonists; Oximes; Phenylcarbamates; Piperidines; Pyridines; Rivastigmine; Tacrine; Thiadiazoles | 1996 |
Pressor and bradycardic effects of tacrine and other acetylcholinesterase inhibitors in the rat.
Topics: Adrenergic Antagonists; Animals; Antidiuretic Hormone Receptor Antagonists; Atropine; Atropine Derivatives; Blood Pressure; Carbamates; Cardiovascular Agents; Chlorisondamine; Cholinergic Antagonists; Cholinesterase Inhibitors; Diamines; Diastole; Dose-Response Relationship, Drug; Heart Rate; Male; Phenylcarbamates; Physostigmine; Piperidines; Pirenzepine; Rats; Rats, Wistar; Rivastigmine; Systole; Tacrine | 1998 |
[Drug therapy strategies in Alzheimer's disease].
Topics: Aggression; Alzheimer Disease; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Depression; Donepezil; Humans; Indans; Mental Disorders; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Sleep Wake Disorders; Tacrine | 1998 |
[Alzheimer's disease. Foreword].
Topics: Age Factors; Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 1998 |
Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats.
Topics: Acetylcholine; Acetylcholinesterase; Administration, Oral; Animals; Brain; Carbamates; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Extracellular Space; Hippocampus; Indans; Male; Phenylcarbamates; Piperidines; Rats; Rats, Wistar; Rivastigmine; Tacrine | 1999 |
Effect of donepezil hydrochloride (E2020) on extracellular acetylcholine concentration in the cerebral cortex of rats.
Topics: Animals; Benzazepines; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Chromatography, High Pressure Liquid; Donepezil; Electrochemistry; Extracellular Space; Indans; Male; Microdialysis; Nootropic Agents; Peripheral Nervous System; Phenylcarbamates; Piperidines; Rats; Rats, Wistar; Rivastigmine; Tacrine | 1999 |
Effect of rivastigmine on scopolamine-induced memory impairment in rats.
Topics: Animals; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Corpus Striatum; Drug Therapy, Combination; Hippocampus; Male; Maze Learning; Memory; Muscarinic Antagonists; Muscle, Skeletal; Phenylcarbamates; Rats; Rats, Sprague-Dawley; Rivastigmine; Scopolamine; Tacrine | 1999 |
New drugs for Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Donepezil; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperidines; Practice Guidelines as Topic; Rivastigmine; Tacrine | 1999 |
Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease, on cholinesterase activity in rats.
Topics: Administration, Oral; Alzheimer Disease; Animals; Benzazepines; Brain; Carbamates; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Indans; Learning; Male; Memory; Phenylcarbamates; Piperidines; Rats; Rats, Wistar; Rivastigmine; Tacrine | 2000 |
The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different.
Topics: Aged; Alzheimer Disease; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Receptors, Nicotinic; Rivastigmine; Tacrine | 2000 |
Comparison of donepezil-, tacrine-, rivastigmine- and metrifonate-induced central and peripheral cholinergically mediated responses in the rat.
Topics: Animals; Body Temperature; Carbamates; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Hypothermia; Indans; Lacrimal Apparatus; Male; Phenylcarbamates; Piperidines; Rats; Rivastigmine; Saliva; Tacrine; Tremor; Trichlorfon | 2000 |
Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro.
Topics: Acetylcholinesterase; Alzheimer Disease; Aminoquinolines; Animals; Benzazepines; Brain; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Donepezil; In Vitro Techniques; Indans; Inhibitory Concentration 50; Male; Phenylcarbamates; Physostigmine; Piperidines; Rats; Rivastigmine; Tacrine; Time Factors | 2000 |
Medications for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Antioxidants; Carbamates; Cholinesterase Inhibitors; Donepezil; Estrogen Replacement Therapy; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 2001 |
Maintaining functional and behavioral abilities in Alzheimer disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Galantamine; Humans; Indans; Neuropsychological Tests; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine; Treatment Outcome | 2001 |
Evaluation of cholinergic treatment in demented patients by P300 evoked related potentials.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Carbamates; Cholinesterase Inhibitors; Cognition; Donepezil; Evaluation Studies as Topic; Event-Related Potentials, P300; Female; Humans; Indans; Male; Middle Aged; Neuropsychological Tests; Phenylcarbamates; Piperidines; Reaction Time; Rivastigmine; Sensitivity and Specificity; Severity of Illness Index; Tacrine | 2001 |
Effects of huperzine A on acetylcholinesterase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmine.
Topics: Acetylcholinesterase; Alkaloids; Animals; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Corpus Striatum; Donepezil; Hippocampus; Indans; Isoenzymes; Kinetics; Male; Phenylcarbamates; Physostigmine; Piperidines; Rats; Rats, Sprague-Dawley; Rivastigmine; Sesquiterpenes; Tacrine | 2002 |
Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy.
Topics: Adult; Aged; Aged, 80 and over; Carbamates; Cholinesterase Inhibitors; Dementia; Donepezil; Dose-Response Relationship, Drug; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Humans; Indans; Memantine; Middle Aged; Phenylcarbamates; Piperidines; Product Surveillance, Postmarketing; Rivastigmine; Surveys and Questionnaires; Tacrine; Treatment Outcome | 2003 |
Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors.
Topics: Allosteric Regulation; Animals; Carbamates; Cells, Cultured; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Mice; Neurons; Phenylcarbamates; Piperidines; Receptors, Muscarinic; Receptors, Nicotinic; Recombinant Fusion Proteins; Rivastigmine; Tacrine; Trichlorfon | 2003 |
Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.
Topics: Acetylcholinesterase; Alzheimer Disease; Benzazepines; Brain; Butyrylcholinesterase; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Edrophonium; Humans; In Vitro Techniques; Phenylcarbamates; Physostigmine; Rivastigmine; Tacrine; Trichlorfon | 2003 |
Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients.
Topics: Acetylcholinesterase; Aged; Alternative Splicing; Alzheimer Disease; Blotting, Western; Carbamates; Centrifugation, Density Gradient; Cerebrospinal Fluid; Cerebrospinal Fluid Proteins; Cholinesterase Inhibitors; Cognition Disorders; Female; Humans; Isoenzymes; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Parietal Lobe; Phenylcarbamates; Rivastigmine; Tacrine; Time | 2004 |
Enhancement of purinergic neurotransmission by galantamine and other acetylcholinesterase inhibitors in the rat vas deferens.
Topics: Acetylcholine; Acetylcholinesterase; Animals; Cholinesterase Inhibitors; Donepezil; Drug Synergism; Electric Stimulation; Galantamine; In Vitro Techniques; Indans; Male; Muscle Contraction; Muscle, Smooth; Nicotine; Nicotinic Agonists; Phenylcarbamates; Physostigmine; Piperidines; Rats; Rats, Wistar; Receptors, Purinergic; Rivastigmine; Stimulation, Chemical; Synaptic Transmission; Tacrine; Vas Deferens | 2004 |
Cholinergic drugs potentiate human nicotinic alpha4beta2 acetylcholine receptors by a competitive mechanism.
Topics: Acetylcholine; Alkaloids; Animals; Atropine; Azocines; Binding, Competitive; Cholinergic Agents; Cholinesterase Inhibitors; Dichlorvos; Dose-Response Relationship, Drug; Female; Galantamine; Humans; Membrane Potentials; Models, Biological; Nicotine; Oocytes; Phenylcarbamates; Physostigmine; Plasmids; Quinolizines; Receptors, Nicotinic; Rivastigmine; Scopolamine; Tacrine; Xenopus laevis | 2005 |
Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production.
Topics: Animals; Brain Chemistry; Cholinesterase Inhibitors; Hippocampus; Interleukin-1; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Neostigmine; Oligodeoxyribonucleotides; Oligonucleotides; Oligonucleotides, Antisense; Phenylcarbamates; Rivastigmine; Tacrine | 2005 |
Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease.
Topics: Aged; Alkaloids; Alzheimer Disease; Brain; Caregivers; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Diagnostic and Statistical Manual of Mental Disorders; Galantamine; Geriatric Psychiatry; Health Services for the Aged; Humans; Phenylcarbamates; Professional-Family Relations; Rivastigmine; Sesquiterpenes; Tacrine; United States | 2006 |
Effect of anti-dementia drugs on LPS induced neuroinflammation in mice.
Topics: Acetylcholinesterase; Analysis of Variance; Animals; Brain; Cholinesterase Inhibitors; Dementia; Donepezil; Dose-Response Relationship, Drug; Indans; Inflammation; Injections, Intraperitoneal; Interleukin-2; Lipopolysaccharides; Mice; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 2007 |
Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies.
Topics: Aged; Aged, 80 and over; Amyloid beta-Peptides; Autopsy; Cerebral Cortex; Cholinesterase Inhibitors; Clinical Trials as Topic; Cohort Studies; Donepezil; Drug Evaluation; Female; Galantamine; Humans; Indans; Lewy Body Disease; Male; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Piperidines; Prospective Studies; Rivastigmine; Tacrine; tau Proteins; Tauopathies | 2007 |
Evaluation of centrally acting cholinesterase inhibitor exposures in adults.
Topics: Adult; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Donepezil; Female; Galantamine; Gastrointestinal Diseases; Humans; Indans; Male; Middle Aged; Phenylcarbamates; Piperidines; Poison Control Centers; Retrospective Studies; Rivastigmine; Tacrine | 2007 |
Summaries for patients. Drug treatment for patients with dementia: American College of Physicians and American Academy of Family Physicians recommendations.
Topics: Activities of Daily Living; Affect; Cholinesterase Inhibitors; Cognition; Dementia; Donepezil; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Quality of Life; Rivastigmine; Tacrine | 2008 |
Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians.
Topics: Activities of Daily Living; Affect; Cholinesterase Inhibitors; Cognition; Dementia; Donepezil; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Quality of Life; Rivastigmine; Tacrine | 2008 |
AAFP and ACP release guideline on dementia treatment.
Topics: Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Guidelines as Topic; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 2008 |
Inhibitory potency of choline esterase inhibitors on acetylcholine release and choline esterase activity in fresh specimens of human and rat neocortex.
Topics: Acetylcholine; Adolescent; Adult; Aged; Animals; Child; Child, Preschool; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Galantamine; Humans; In Vitro Techniques; Indans; Middle Aged; Neocortex; Phenylcarbamates; Physostigmine; Piperidines; Rats; Rats, Wistar; Rivastigmine; Tacrine; Young Adult | 2009 |
Cortical EEG oscillations and network connectivity as efficacy indices for assessing drugs with cognition enhancing potential.
Topics: Animals; Cerebral Cortex; Cognition; Donepezil; Drug Evaluation, Preclinical; Electrodes, Implanted; Electroencephalography; Galantamine; Gamma Rhythm; Indans; Male; Memantine; Motor Activity; Muscarinic Antagonists; Neural Pathways; Nootropic Agents; Phenylcarbamates; Piperidines; Principal Component Analysis; Rats, Sprague-Dawley; Rivastigmine; Scopolamine; Signal Processing, Computer-Assisted; Tacrine; Theta Rhythm | 2014 |
Effect of Donepezil, Tacrine, Galantamine and Rivastigmine on Acetylcholinesterase Inhibition in Dugesia tigrina.
Topics: Animals; Cholinesterase Inhibitors; Convulsants; Donepezil; Galantamine; Indans; Locomotion; Models, Biological; Piperidines; Planarians; Rivastigmine; Seizures; Survival Rate; Tacrine | 2016 |
Novel Tacrine-Based Pyrano[3',4':5,6]pyrano[2,3-b]quinolinones: Synthesis and Cholinesterase Inhibitory Activity.
Topics: Acetylcholinesterase; Amyloid Precursor Protein Secretases; Animals; Binding Sites; Butyrylcholinesterase; Cell Death; Cholinesterase Inhibitors; Hydrogen Peroxide; Models, Molecular; Molecular Docking Simulation; Neuroprotective Agents; Quinolones; Rivastigmine; Structure-Activity Relationship; Tacrine | 2016 |
Therapeutic Potential of Multifunctional Derivatives of Cholinesterase Inhibitors.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Galantamine; Rivastigmine; Tacrine | 2021 |
In silico and in vitro studies confirm Ondansetron as a novel acetylcholinesterase and butyrylcholinesterase inhibitor.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Humans; Molecular Docking Simulation; Ondansetron; Rivastigmine; Structure-Activity Relationship; Tacrine | 2023 |